Ahmed F Sherief

Dr. Ahmed F Sherief

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
HDHany M. Dabbous
Hany M. Dabbous
SASherief Abd-Elsalam
Sherief Abd-Elsalam
MEManal H. El-Sayed
Manal H. El-Sayed
ASAhmed F Sherief
Ahmed F Sherief
FEFatma F. S. Ebeid
Fatma F. S. Ebeid
MTMohamed Awad Tageldin
Mohamed Awad Tageldin

6 March 2021 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
MBMaha Abdelmoneim Behairy
Maha Abdelmoneim Behairy
ASAhmed F Sherief
Ahmed F Sherief
HHHany Aly Hussein
Hany Aly Hussein

15 August 2019 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
MEMohamed El-Kassas
Mohamed El-Kassas
MAMohamed Alboraie
Mohamed Alboraie
MNMervat Naguib
Mervat Naguib
HOHeba Omar
Heba Omar
ATAdel El Tahan
Adel El Tahan
DODalia Omran
Dalia Omran
Background/Aims: There is less data regarding the changes in body mass index (BMI) after treating hepatitis C virus (HCV) patients with new direct-acting antiviral agents (DAAs). This study aimed to assess the changes in BMI in chronic HCV patients treated with DAAs in Egypt and to explore other factors influencing this change. Materials and Methods: The data of chronic HCV patients who received antiviral therapy with new DAAs in one of Egypt’s specialized viral hepatitis treatment centers were retrospectively analyzed. In addition to the routine clinical and laboratory workup, changes in body weight during and after treatment were monitored and BMI was calculated. Viral load was measured at 12 weeks post-treatment to assess a sustained virological response. Patients with documented thyroid abnormalities, bariatric surgery, or ensuing special diets were excluded. BMI of >30 was taken as the cutoff for pa¬tients with obesity. Results: The study included 162 patients with a mean age of 48.56±11.49 years, of whom 61.1% were males, 16% were treatment-experienced, 12% were diabetic, and 29% were obese. Treatment duration was 12 weeks in 84% of patients and 24 weeks in 16% of patients. There was a significant increase in BMI post-treatment as compared to pretreatment measures (28.68±5.35 vs 28.18±4.55) (p=0.03). BMI changes were constant regardless of cirrhosis or previous treatment experience. Conclusion: Treatment of chronic HCV with DAAs was associated with increased body mass index. Further studies are needed to explore if this effect is secondary to treatment with DAAs or is an improvement in the liver function and lifestyle of treated patients.

22 November 2021 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
HDHany M. Dabbous
Hany M. Dabbous
SASherief Abd-Elsalam
Sherief Abd-Elsalam
MEManal H. El‑Sayed
Manal H. El‑Sayed
ASAhmed F Sherief
Ahmed F Sherief
FEFatma F. S. Ebeid
Fatma F. S. Ebeid
MTMohamed Awad Tageldin
Mohamed Awad Tageldin

1 October 2021 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
NANadia Abdelaaty Abdelkader
Nadia Abdelaaty Abdelkader
ABAmira Al Balakosy
Amira Al Balakosy
ASAhmed F Sherief
Ahmed F Sherief
MGMohamed Soliman Gado
Mohamed Soliman Gado
Background: Hepatitis C virus (HCV) infection affects approximately 170 million people worldwide, causing liver cirrhosis and hepatocellular carcinoma (HCC) and leading to liver transplantation and ultimately death. Accurate evaluation of liver fibrosis in patients with chronic liver diseases is crucial, as liver fibrosis is important in order to make therapeutic decisions, determine prognosis of liver disease and to follow-up disease progression. Multiple non-invasive methods have been used successfully in the prediction of fibrosis; however, early changes in noninvasive biomarkers of hepatic fibrosis under effective antiviral therapy are widely unknown. The aim of this study is to evaluate changes of transient elastography values as well as FIB-4 and AST to platelet ratio index (APRI) in patients treated with DAAs. Objectives: The aim beyond this study is to evaluate the changes in liver stiffness in hepatitis C Egyptian patients before and at least one year after treatment with DAAs using transient elastography and non-invasive liver fibrosis indices as FIB-4 and APRI scores. Patients and methods: The present study was conducted on 100 patients with chronic hepatitis C patients attended to Ain Shams University Hospitals, Viral hepatitis treatment unit between October 2017 and December 2018, who were followed-up during treatment and after treatment for at least one year (retrospective and prospective study). Total number of cases during the study period was 117 patients. 17 patients were excluded from the study due to missed follow-up. Eventually, 100 patients were enrolled in the study fulfilling the inclusion criteria. Results: The mean age of our patients is 47.9 years with Male predominance (52 males and 48 females). There was a significant improvement of, platelets counts, ALT and AST levels, which in turn cause significant improvement in FIB-4 and APRI scores. There was a significant improvement of liver stiffness after end of treatment, regardless of the DAA regimen used, as evidenced by Fibroscan. Conclusion: Fibrosis regression –assessed by non-invasive markers of fibrosis is achievable upon removal of the causative agent.

22 October 2022 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
MEMohamed El-Kassas
Mohamed El-Kassas
SESherif Elbehiry
Sherif Elbehiry
EREnas Rezk
Enas Rezk
DODalia Omran
Dalia Omran
ASAhmed F Sherief
Ahmed F Sherief
AMAhmed Madkour
Ahmed Madkour